{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037590","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.067923+00:00","generated_at":"2026-06-12T08:52:42.175602+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BridgeBio Q2 net loss $157.9M; acoramidis Phase 3 ATTR-CM meets primary endpoint, NDA planned by end 2023","bullets":["Phase 3 ATTRibute-CM of acoramids achieved highly significant primary endpoint, Win Ratio 1.8 (p<0.0001); NDA filing planned by end 2023.","Revenue $1.6M in Q2 vs $73.7M prior year due to $70.2M one-time license in 2022; net loss $157.9M.","Cash & equivalents $353.2M; mgmt expects $300-350M to support acoramidis launch.","Announced positive infigratinib Phase 2 results in achondroplasia; mean AHV +3.38 cm/year.","BBP-418 Phase 3 FORTIFY trial dosed first patient; FDA discussion supports accelerated approval potential."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037590","json":"https://secwatch.observer/filing/0000950170-23-037590.json","markdown":"https://secwatch.observer/filing/0000950170-23-037590.md","text":"https://secwatch.observer/filing/0000950170-23-037590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000095017023037590/0000950170-23-037590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000095017023037590/bbio-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:52:42.175602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea7b99c1fdfe73d96a83765eac34e05af2423c17","claim":"BridgeBio Pharma, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, BridgeBio Pharma, Inc. reported recent business updates and its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017023037590/0000950170-23-037590-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}